PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sereflo Ciphaler (Salmeterol / Fluticasone) DPI - Chronic Obstructive Pulmonary Disease (COPD)

PAD Profile : Sereflo Ciphaler (Salmeterol / Fluticasone) DPI - Chronic Obstructive Pulmonary Disease (COPD)

Brand Names Include :
Sereflo Ciphaler

Traffic Light Status

Status 1 of 1.

Status :
N/A
Formulations :
  • Inhaler (dry powder)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD2
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
28 February 2024
Not Set

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Associated BNF Codes

03. Respiratory System
03.02.00. Corticosteroids (respiratory)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More